21h
Hosted on MSNEC approves CSL’s Andembry to stop hereditary angioedema attacksCSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...
CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal has recommended ORLADEYO® ...
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved ...
Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term ...
The European Commission (EC) has approved Andembry (garadacimab), the first and only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and ...
The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...
Pharmaceuticals announced that Infarmed in Portugal has recommended ORLADEYO for the routine prevention of recurrent attacks of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results